These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29559598)

  • 21. [Clinical efficacy of ozonated oil in the treatment of psoriasis vulgaris].
    Tan L; Huang J; Lu J; Lu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Feb; 43(2):173-178. PubMed ID: 29559602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated interleukin-33 and soluble ST2 levels in the sera of patients with pemphigus vulgaris: correlation with clinical and immunological parameters during follow-up.
    Tirado-Sánchez A; Bonifaz A; Ponce-Olivera RM
    Br J Dermatol; 2015 Sep; 173(3):818-20. PubMed ID: 25645746
    [No Abstract]   [Full Text] [Related]  

  • 23. Extensive keloid formation after pemphigus vulgaris.
    Sako EY; Workwick S
    Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pemphigus vulgaris--malignant course].
    Steiner A; Diem E
    Hautarzt; 1986 Sep; 37(9):499-502. PubMed ID: 3533847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
    Morrison LH
    J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris.
    Mabrouk D; Ahmed AR
    Pediatr Dermatol; 2011; 28(5):485-93. PubMed ID: 21883426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris.
    Pazoki-Toroudi H; Nilforoushzadeh MA; Ajami M; Jaffary F; Aboutaleb N; Nassiri-Kashani M; Firooz A
    Cutan Ocul Toxicol; 2011 Dec; 30(4):286-91. PubMed ID: 21612319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
    Feldman RJ; Christen WG; Ahmed AR
    Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab.
    Jacobi A; Shuler G; Hertl M
    Br J Dermatol; 2005 Aug; 153(2):448-9. PubMed ID: 16086769
    [No Abstract]   [Full Text] [Related]  

  • 30. Complete remission after rituximab therapy in an HIV-positive patient with pemphigus vulgaris.
    Polansky M; Patel N; Feldman R
    Br J Dermatol; 2015 Dec; 173(6):1557-9. PubMed ID: 26122850
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
    Turner MS; Sutton D; Sauder DN
    J Am Acad Dermatol; 2000 Dec; 43(6):1058-64. PubMed ID: 11100023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The management of pemphigus vulgaris in a burn intensive care unit: a case report and treatment review.
    Miletta N; Miller ME; Lam T; Chung KK; Hivnor C
    J Burn Care Res; 2014; 35(5):e357-63. PubMed ID: 24572296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oropharyngeal pemphigus vulgaris and clinical remission: a long-term, longitudinal study.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E
    Am J Clin Dermatol; 2010; 11(2):137-45. PubMed ID: 20141235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris.
    Dietze J; Hohenstein B; Tselmin S; Julius U; Bornstein SR; Beissert S; Günther C
    Atheroscler Suppl; 2017 Nov; 30():271-277. PubMed ID: 29096849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hydrozotomy: a therapeutic method using ozone].
    Sandhaus S
    SSO Schweiz Monatsschr Zahnheilkd; 1968 Jun; 78(6):620-3. PubMed ID: 5252529
    [No Abstract]   [Full Text] [Related]  

  • 36. Pemphigus: update for the general practitioner.
    Stoopler ET; Pinto A; DeRossi SS
    N Y State Dent J; 2003; 69(7):30-2. PubMed ID: 14552023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The perioperative management of the patient with pemphigus vulgaris and villous adenoma.
    Lavie CJ; Thomas MA; Fondak AA
    Cutis; 1984 Aug; 34(2):180-2. PubMed ID: 6478881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study.
    Ioannides D; Apalla Z; Lazaridou E; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):855-60. PubMed ID: 21752101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab therapy failure in two patients with pemphigus vulgaris.
    García-Rabasco A; Alsina-Gibert M; Pau-Charles I; Iranzo P
    J Am Acad Dermatol; 2012 Nov; 67(5):e196-7. PubMed ID: 23062908
    [No Abstract]   [Full Text] [Related]  

  • 40. Pemphigus vulgaris and laser therapy: crucial role of dentists.
    Pavlić V; Aleksić VV; Zubović N; Veselinović V
    Med Pregl; 2014; 67(1-2):38-42. PubMed ID: 24964567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.